Danny Yeung is the Co-Founder of Prenetics and has served as Chief Executive Officer since its inception in 2014. Mr. Yeung’s journey into healthcare started as a way to utilize his extensive entrepreneurial career into making an impact for society. Mr. Yeung’s vision from day 1 was to always turn Prenetics into a global health company, recruiting the best talent, and to give everyone the power to be in control of their own health.

Prior to Prenetics, Mr. Yeung was a Founding Partner at SXE Ventures, having led multiple investments in genetic testing companies and in Honey Science, which was acquired by Paypal for US $4 billion in 2019. Mr. Yeung had also founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to leaving Groupon in early 2014, Mr. Yeung served as CEO of Groupon East Asia, leading it to be the largest e-commerce company in the region. Mr. Yeung’s entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong dessert chain “Hui Lau Shan” into the USA. After exiting Hui Lau Shan, Mr. Yeung successfully ventured into hospitality furniture and executed multi-million-dollar projects with MGM globally. Mr. Yeung’s life motto is “Play Hard, Work Harder”.

Stephen has served as the Chief Financial Officer of Prenetics since 2018, and oversees the financial operations, corporate accounting and reporting, treasury, financial and tax planning and analysis and investor relations. Prior to joining Prenetics, Mr. Lo was in the Asia Pacific Investment Banking team of Citigroup, where he worked extensively on initial public offering transactions, placements, debt issuances and cross border mergers and acquisitions in Asia and the U.S. between 2014 and 2018. From 2007 to 2011, Mr. Lo was an auditor with Ernst & Young.

Mr. Lo received a Master of Business Administration from Yale University’s School of Management, a Master of Science in Accounting and Finance from the London School of Economics and Political Science and a bachelor’s degree in Accounting from Hong Kong Baptist University. Mr. Lo is a Fellow of the Hong Kong Institute of Certified Public Accountants, a Chartered Accountant of the Institute of Chartered Accountants in England and Wales and a CFA Charterholder.

Dr. Lawrence Tzang is the Co-Founder of Prenetics and has served as its Chief Scientific Officer and director since its founding in 2014. He has more than 20 years of experience in molecular diagnostics, genomics as well as laboratory automation. Dr. Tzang has been a registered Medical Laboratory Technologist I at the Board of Medical Laboratory Technologist since 2013, a founding member and ex-secretary at the Hong Kong Society for Behavioral and Neural Genetics in 2011-2022 and a fellow of the Hong Kong Society for Molecular Diagnostic Sciences since 2008. Dr. Tzang received his Ph.D. in Molecular Biology in 2003 and post-doctoral research fellowship at Department of Biology & Chemistry of the City University of Hong Kong from 2003 to 2009.

Dr. Tzang used microarray technologies on gene expression profiling for cancer researches, including vimentin and clusterin gene expression in hepatocellular carcinoma metastasis and key role of a protein in hepatocarcinogenesis, as well as drug resistance in cervical carcinoma. Dr. Tzang has also developed a biochip based genotyping platform for human papillomavirus genotyping and prevalence analysis in cervical cancer. In addition, he also participated in deep proteome profiling of sera from never-smoked lung cancer patients.

Joel Neoh is a serial entrepreneur and technology executive with over 15 years of top-flight leadership and board experience. Joel’s experience in consumer technology spans sectors such as fintech, e-commerce, digital media, and health & wellness. Most recently, Joel was the founder of Fave, a leading Southeast Asian fintech platform backed by Sequoia Capital and acquired by Pine Labs, a unicorn company. Joel has been instrumental in accelerating digital payments and financial services for millions of consumers and merchants. Previously, Joel was the founder of GroupsMore, which was acquired by Groupon. While at Groupon, Joel headed up its Asia Pacific business, overseeing more than 2,000 employees. Joel’s entrepreneurial journey started out by co-founding Says.com, one of Malaysia’s largest digital news platforms. Joel is also a Board Director for the Institute of Corporate Directors Malaysia, promoting excellence in corporate governance. His entrepreneurial success and leadership led to his recognition as Ernst & Young Emerging Entrepreneur of the Year (Malaysia) in 2012, and as a Young Global Leader by the World Economic Forum in 2013.

Dr. Peter Wong is the Chief Technology Officer of Prenetics. Since he joined in 2017, Dr. Wong has been leading Prenetics’ global technology vision and roadmap, and engineering delivery. Prior to Prenetics, Dr. Wong was the Head of Engineering at Travelex, where he led Travelex’s first digital transformation and B2B business. Dr. Wong also successfully delivered a brand new international money transfer service, Travelex Wire, and launched Travelex’s first international payment platform with the World Bank Group. Dr. Wong has experience across various industries including investment banking and eCommerce; and is a frequent speaker at technology events including AWS Summit and various universities. Dr. Wong holds a Doctorate degree in Computer Science from the University of Oxford, and B.Sc. and M.Sc. degrees in Computer Science from the University of Warwick.

Dr. Senthil Sundaram is the Chief Clinical Officer of Prenetics, and is responsible for overseeing the clinical policies. Dr. Sundaram is highly recognised for his experience as a physician-scientist, having led numerous genetic research programs in the USA. Dr. Sundaram has discovered genetic mutations and rare genetic variants causing different neurological diseases using cutting edge next-generation sequencing technologies such as whole exome sequencing. Dr. Sundaram’s research articles have been published in reputed, high-impact journals such as Neurology, Annals of Neurology, Cerebral Cortex and others. Dr. Sundaram’s research works were funded by the National Institute of Health (NIH), USA. Dr. Sundaram also served as a reviewer of different journals and NIH study sections.

Samantha Kwok is the Chief of Staff to Group CEO and Vice President, People & Operations, of Prenetics, and is responsible for all the overall people strategy, global talent acquisition, leadership development, organizational design, and delivering an inclusive employee and candidate experience which reflects Prenetics vision, mission and values. Samantha works with leaders across Prenetics’ different lines of business to support their dynamic needs, and is focused on developing and implementing strategies which drive business results and foster a positive and creative work environment. Prior to Prenetics, Samantha had extensive recruitment and HR consulting experience across Greater China, advising and consulting for many of China’s largest tech companies including Alibaba, VIPKID, Didi, Bytedance, Binance and Xiaomi, Daimler and FGS Global through her own entrepreneurial ventures. Samantha was also Chief of Staff, People and Operations at multiple tech startups, consumer brands and B2B platforms, helping several international brands launch and expand successfully throughout APAC. Samantha holds a degree in political, economic and social sciences from the University of Sydney.

Jordan Lemerande is the Vice President of Product Development (Nutraceuticals) at Prenetics. She brings a wealth of experience in dietary supplement innovation, research, development, and production. In her role, Jordan oversees product strategy, formulation, and innovation management. She works closely with organizational leaders to ensure products align with Prenetics' mission and values, and collaborates with suppliers and manufacturers to maintain product integrity and sustainability.  Additionally, she partners with the scientific advisory board to incorporate the latest scientific advancements into Prenetics' products.

Jordan's extensive background includes roles in R&D and product development at some of the largest dietary supplement brands and contract manufacturers, such as Nutrilite/Amway, Nature's Bounty, Jarrow Formulas, Doctor's Best, and Vit-Best Nutrition.  She has successfully led numerous product launches and driven significant sales growth through strategic initiatives.

Her career is distinguished by a commitment to science-based formulation, high quality, and educating others about the benefits of supplements. Jordan is deeply dedicated to upholding the highest standards in product efficacy and quality. She is passionate about creating exceptional supplements that promote health and wellness for all.

Alan Thomas has served as the Vice President of Supply Chain & Operations since March 2024, overseeing supply chain operations for Prenetics. He has over two decades of experience within Global Fortune 500 companies such as Reckitt Benckiser, Linde Gas, and The Nature’s Bounty Co (Nestle), leading manufacturing facilities, transforming operations, and launching products on a global scale. His career has taken him throughout the USA, Puerto Rico, and Canada, where he has been rapidly scaling organisations and building resilient supply chains.

Alan holds a Master of Science degree from Stevens Institute of Technology and a Bachelor of Science in Molecular Biology & Chemistry. As a Six Sigma Black Belt and Lean Operations Leader, he is dedicated to continuous operational improvement and enhancing profit margins through innovative supply chain solutions.

Danny Yeung is the Co-Founder of Prenetics and has served as Chief Executive Officer since its inception in 2014. Mr. Yeung’s journey into healthcare started as a way to utilize his extensive entrepreneurial career into making an impact for society. Mr. Yeung’s vision from day 1 was to always turn Prenetics into a global health company, recruiting the best talent, and to give everyone the power to be in control of their own health.

Prior to Prenetics, Mr. Yeung was a Founding Partner at SXE Ventures, having led multiple investments in genetic testing companies and in Honey Science, which was acquired by Paypal for US $4 billion in 2019. Mr. Yeung had also founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to leaving Groupon in early 2014, Mr. Yeung served as CEO of Groupon East Asia, leading it to be the largest e-commerce company in the region. Mr. Yeung’s entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong dessert chain “Hui Lau Shan” into the USA. After exiting Hui Lau Shan, Mr. Yeung successfully ventured into hospitality furniture and executed multi-million-dollar projects with MGM globally. Mr. Yeung’s life motto is “Play Hard, Work Harder”.

Ms. Henry is currently an independent director at Lululemon, where she has been a board member for more than 8 years and serves as a member of the Audit & Compensation Committee. She provides strategic consulting to consumer retail and technology companies, as well as venture capital, investment, and consulting firms seeking executive-level guidance.

Ms. Henry previously served as Chief Information Officer, Logistics & Distribution at Lululemon from 2010 to 2014, where she oversaw all global information and technology operations for the company.

Prior to joining Lululemon in 2010, Ms. Henry worked at Gap, Inc., where she served as Vice President and Chief Information Officer of International IT and Gap North America. She was responsible for the systems support of key international growth initiatives. Previously, she was Vice President of Dockers Business Divestiture and Vice President of Global IT Strategy & Development at Levi Strauss & Co.

Mr. Vanderveen has had a successful 30-year track record in beverage, nutrition, and technology, leading disruptive change at both private and public companies. From 2022 until recently, he was CEO of Nirvana Water Sciences, where he developed a team of industry beverage, functional beverage, and supplement experts to transform the brand, product portfolio, go-to-market strategy, and execution of the business.

From 2002 to 2015, Mr. Vanderveen was the founder and CEO of XS Worldwide, a company with a portfolio of energy drinks and sports nutrition products. XS partnered with Amway Corporation and became the fastest-growing business segment and category for the world’s largest direct seller, reaching annual sales over $400 million with distribution in more than 60 countries. XS was sold to Amway in 2015, where Mr. Vanderveen served as Vice President and Global General Manager for the XS brand, achieving maximum earn-out through 2018.

Mr. Vanderveen is also an advisor and limited partner at RX3 Growth Partners, a private equity firm that partners with consumer brands and other leading investment firms to maximize value by leveraging its unique influencer base of athletes, celebrities, and thought leaders, and is a general partner in LLB Global Fund, an international arbitration fund in partnership with French law firm, Lazareff Le Bars.

Mr. Ben Cheng has been proposed as an Executive Board Member and CEO of C Capital AG. He serves as the President and CEO of C Capital, a global asset management platform specializing in private equity, private credit fund and blockchain hedge fund strategies. Under his leadership, C Capital has made significant strides in the investment landscape, focusing on transformative opportunities across various sector.

With extensive experience in venture capital and private equity, Mr. Cheng has played a pivotal role in high-profile investments, including CASETiFY, the fastest-growing global tech accessories brand; XiaoPeng (NYSE: XPEV), a leading Chinese electric vehicle manufacturer; Animoca Brands, a multinational blockchain technology; NOTHING, a UK-based consumer electronics manufacturer; Lalamove, a prominent Chinese on-demand logistics firm. He is also a board member of Prenetics Global Limited (Nasdaq: PRE) and holds a Non-executive Director position at Ocean Line Port Development Limited (8502.HK).

In addition to his operational roles, Mr. Cheng actively contributes to the community as a committee member of Hong Kong Trade Development Council Mainland Business Advisory Committee and the Venture Committee of Hong Kong Venture Capital and Private Equity Association. He is also a committee member of The LRC Charitable Foundation (LRCCF).

Prior to C Capital, Mr. Cheng honed his expertise as an investment banker at Bank of America Merrill Lynch and Standard Chartered Bank, where he was involved in landmark transactions such as the US$3.3 billion take-private of WuXi PharmaTech, Temasek’s US$5.7 billion investment in Watson’s and the US$2.1 billion acquisition of ING's insurance business in Hong Kong, Macau and Thailand.

Mr. Cheng’s diverse experience and strategic vision position him as a key leader in the investment community, driving innovation and growth at C Capital and beyond.

Winnie Chiu serves as an Independent Director of Prenetics. Ms. Chiu is also the President and Executive Director of Dorsett Hospitality International, the Executive Director of Far East Consortium International Limited, and the Chairperson of AGORA Hospitality Group Co., Ltd.

Ms. Chiu serves on numerous social committees in various capacities, including the Greater Bay Area Homeland Youth Community Foundation, the Better Hong Kong Foundation, the Community Chest, Our Hong Kong Foundation, the Federation of Hong Kong Hotel Owners and Hong Kong-Japan Business Co-Operation Committee. Ms. Chiu is an active philanthropist primarily focused on arts and education. She is Chairman of the Hong Kong Art School and Joint President of the Society of the Academy for Performing Arts. She also holds positions on the Hong Kong Arts Development Council and on Boards at Hong Kong University and Chinese University of Hong Kong.

Amongst her accolades, Ms. Chiu received Honorary Fellowships from the Hong Kong Academy for Performing Arts and the Vocational Training Council in Hong Kong. She also received the World Outstanding Chinese Youth Award in 2016 and was nominated for Asia’s Power Businesswomen by Forbes in 2014. Ms. Chiu holds a B.Sc from King’s College, University of London.

Dr. Dawn Mussallem is a distinguished consultant in the Division of Hematology Oncology at Mayo Clinic, where she has served as a clinician for over 20 years, and an Assistant Professor of Medicine. She is a board-certified lifestyle medicine breast specialist at The Robert and Monica Jacoby Center for Breast Health and founded the Integrative Medicine and Breast Health Program at Mayo Clinic Florida.
 
A stage IV cancer survivor diagnosed three months into medical school, Dr. Mussallem’s personal journey is a testament to resilience and determination. In 2021, she underwent a heart transplant and remarkably became the first person to run a marathon one year post-transplant. Internationally recognized for her work in cancer prevention and integrative oncology, she is a prolific speaker and author. Her dedication to patient care and innovative approaches align perfectly with Prenetics' mission, making her an invaluable addition to the Medical Advisory Board.

Dr. James L. Green is the former Chief Scientist of NASA, where he dedicated an impressive 42 years to advancing space science and exploration. During his tenure, Dr. Green contributed to numerous groundbreaking missions, including the Mars Rover landings, the New Horizons mission to Pluto, and the Juno mission to Jupiter. He played a pivotal role in the development of planetary defense strategies and was instrumental in fostering international collaborations for space research.

Dr. Green's extensive experience in managing large-scale scientific projects and his deep understanding of cutting-edge technologies bring a unique perspective to Prenetics. His work at NASA also included leveraging space research for health innovations, such as studying the effects of space travel on the human body and accelerated aging. His expertise in scientific innovation and strategic vision will be invaluable in advancing Prenetics' mission to revolutionize healthcare through precision diagnostics and personalized medicine.

David L. Katz, MD, MPH, FACPM, FACP, FACLM, is a specialist in Internal Medicine, Preventive Medicine/Public Health, and Lifestyle Medicine, with particular expertise in nutrition. He earned his BA at Dartmouth College (1984); his MD at the Albert Einstein College of Medicine (1988); and his MPH from the Yale University School of Public Health (1993).  

Katz is the founder and former director of Yale University’s Yale-Griffin Prevention Research Center (1998-2019); Past President of the American College of Lifestyle Medicine; Founder of the non-profit True Health Initiative; and Founder of Diet ID, Inc, and Chief Medical Officer for Tangelo. He is a Fellow of the American College of Preventive Medicine; the American College of Physicians; the American College of Lifestyle Medicine; and Morse College, Yale University.

The recipient of numerous awards for teaching, writing, and contributions to public health, Katz was a 2019 James Beard Foundation Award nominee in health journalism, is a 2023 recipient of a Lifetime Achievement Award from the Doctors’ World Gala, and has received three honorary doctorates.  

He holds multiple US patents; has roughly 250 peer-reviewed publications; and has authored/co-authored 19 books to date including multiple editions of leading textbooks in nutrition, preventive medicine, and epidemiology.

Dr. Suzanne Devkota is a leading expert in microbiome research and its impact on human health, with over 15 years of experience in the field. She is an Associate Professor at Cedars-Sinai Medical Center and the Director of the Microbiome Research Institute. Dr. Devkota’s groundbreaking work focuses on understanding the role of the gut microbiome in chronic diseases, including inflammatory bowel disease, obesity, and diabetes. She has published extensively in top scientific journals and is a sought-after speaker at international conferences.

Dr. Devkota’s research emphasizes the critical connection between the microbiome and overall health, highlighting the potential for microbiome-based therapies. Her insights into how diet and lifestyle influence the gut microbiome align closely with Prenetics' mission to advance health through innovative diagnostics and personalized medicine. Dr. Devkota’s expertise in microbiome science will be invaluable in helping Prenetics develop cutting-edge solutions to improve health outcomes and foster preventative care.

Prof. Stephen Anton is a renowned expert in aging and metabolic health, with over 20 years of experience in the field. He is a Distinguished Professor at the University of Florida with a primary appointment in the Department of Physiology and Aging. Prof. Anton’s research focuses on the interplay between lifestyle factors, metabolic health, and aging, with a particular emphasis on the benefits of caloric restriction, intermittent fasting, and physical activity. He has authored numerous scientific publications and is a frequent speaker at national and international conferences.

Prof. Anton’s extensive work highlights the potential of lifestyle interventions in promoting healthy aging and preventing metabolic diseases. His insights into the mechanisms of aging and metabolic regulation are highly relevant to Prenetics' mission of leveraging advanced diagnostics and personalized health strategies. Prof. Anton’s expertise is invaluable in helping Prenetics develop innovative solutions to enhance healthspan and improve metabolic health outcomes.

Dr. James DiNicolantonio is a cardiovascular research scientist and Doctor of Pharmacy, known for his influential work in the field of heart health and evidence-based nutrition. Author of several bestselling books, including The Obesity Fix and Superfuel, he has published over 300 scientific papers, focusing on the impact of nutrition on long-term health and chronic disease prevention. His work provides valuable insights into optimizing well-being through natural and scientifically supported methods.

A respected authority in the health and wellness community, Dr. DiNicolantonio’s approach centers on simplifying complex scientific concepts, making health strategies accessible to a broad audience. He advocates for a proactive approach to wellness, combining cutting-edge research with practical applications to help individuals achieve peak physical and mental performance. His focus on heart health and longevity has made him a key figure for those looking to improve their overall well-being through informed lifestyle choices.

Prof. Ock Chun is a distinguished expert in nutritional sciences with over 25 years of experience in the field. She is a Professor in the Department of Nutritional Sciences at the University of Connecticut. Prof. Chun’s research focuses on the relationship between diet, nutrition, and chronic diseases, with significant contributions to understanding the role of dietary bioactive compounds in cancer prevention and metabolic health. She has published extensively in high-impact scientific journals and is a respected figure in the academic and research communities.

Prof. Chun's work emphasizes the critical role of nutrition in disease prevention and health promotion. Her insights into how dietary factors influence health outcomes align closely with Prenetics' mission to advance healthcare through precision diagnostics and personalized nutrition strategies. Prof. Chun's expertise in nutritional sciences will be invaluable in helping Prenetics develop innovative solutions to enhance health and prevent chronic diseases through tailored dietary interventions.


Prof. Mok will lead the SAB and currently serves as Chairman of the Department of Clinical Oncology of Chinese University of Hong Kong, is a non-executive director of AstraZeneca plc (LON:AZN), and an independent director of HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 0013). His main research interest focuses on biomarker and molecular targeted therapy in lung cancer.

Prof. Mok was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple studies including the FASTACT 2, IMPRESS, ARCHER 1050, ALEX and AURA 3. These projects address various aspects on management of EGFR mutation positive lung cancer, and have played a significant role in defining current practice. Prof. Mok has also engaged in clinical research on ALK positive lung cancer and immunotherapy. The series of clinical trials, led or co-led by Professor Mok, have defined precision medicine. His work has been adopted by multiple international guidelines including NCCN, AMP/IASLC/CAP, ASCO and ESMO.

Prof. Pasi Jänne is a globally renowned translational thoracic medical oncologist at the Dana Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He is also the Director of the Lowe Center for Thoracic Oncology and the Director of the Belfer Center for Applied Cancer Science. Prof. Jänne's research combines laboratory-based study with translational research in clinical trial of novel therapeutic agents in patients with lung cancer. He has made seminal therapeutic discovery including co-discovery of EGFR mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer.

Prof. Pasi Jänne's translational research work also led to the successful development of HER3-ADC in NSCLC and combination with Osimertinib to further enhance the potential efficacy of HER3-ADC. Prof. Jänne has received multiple awards for his work including from the AACR, ESMO and ASCO.

Prof. Yang is the former President of Taiwan University and has been a professor in the department of internal medicine at the College of Medicine for 27 years. He has also served as the Director of the Advisory Office for the Ministry of Education and as Dean for the College of Medicine at Taiwan University. Dr. Yang was honoured with the Joseph W. Cullen Prevention/Early Detection Award at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer.

Prof. Yang is a pioneer and leader in pulmonary ultrasound diagnostics and therapeutics that have revolutionized the management of pulmonary diseases which include lung cancer. He has led a research group to develop the method for detection and quantification circulating cancer cells in peripheral blood and to better predict the prognosis and response to treatment for lung cancer patients. His has led a research group to discover novel genes and pathways that associated with lung cancer pathogenesis and progression. They identified specific gene expression and microRNA signatures that can assist to predict the treatment outcome and may be beneficial for personalized therapy of lung cancer patients.